Navigation Links
New Nexavar Data Presented in Multiple Tumor Types at 44th American Society of Clinical Oncology Annual Meeting
Date:6/2/2008

se events included fatigue, hand/foot syndrome and skin rash.

The lead investigator for this study is Joan Schiller, MD, professor and chief of the hematology/oncology division at the University of Texas Southwestern and Andrea L. Simmons distinguished chair in cancer research, Dallas, TX. (abstract #8014).

Thyroid Cancer

A Phase 2 Study of Sorafenib in Metastatic Thyroid Carcinoma

Findings from this single-arm Phase 2 study showed that treatment with Nexavar resulted in meaningful anti-tumor activity in the majority of patients with encouraging overall clinical benefit (disease stabilization and partial responses) in patients with advanced thyroid cancer. In the study, Nexavar was well-tolerated; the most common treatment-related adverse events included fatigue, rash, diarrhea, palmer-plantar erythema, musculoskeletal pain and weight loss. Patients enrolled in this study had been diagnosed with metastatic, iodine-refractory, unresectable or locally-advanced thyroid cancer.

The lead investigator for this study is Marcia S. Brose, MD, PhD, assistant professor, director of cancer genetics laboratory, University of Pennsylvania Health System, Philadelphia, PA. (abstract #6026).

Gastrointestinal Stromal Tumors

Activity of Sorafenib in Patients with Imatinib and Sunitinib-Resistant Gastrointestinal Stromal Tumors (GIST): A Phase 2 Trial of the University of Chicago Phase 2 Consortium

Findings from this single-arm Phase 2 study suggest that Nexavar is active and well tolerated in patients with Gleevec or Gleevec and Sutent resistant GIST. The most common treatment-emergent adverse events included hand-foot syndrome, hypertension, rash and diarrhea.

The lead investigator for this study is Lauren Wiebe, MD, fellow, University of Chicago, Chicago, IL. (abstract #10502).

Gastric/GEJ

A Phase 2 Study: Combination of Sorafenib with Docetaxel and Cisplatin in the Treatment of Metastatic or Advanced Unres
'/>"/>

SOURCE Bayer HealthCare Pharmaceuticals, Inc.; OnyxPharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
2. Nexavar First FDA-Approved Drug Therapy for Liver Cancer
3. ZymoGenetics Reports Positive Phase 1 Results for IL-21 With Nexavar(R)
4. Nexavar Significantly Improved Overall Survival in Phase 3 Asia-Pacific Liver Cancer Trial
5. Preliminary Data from Ongoing Phase 1 Data of Investigational Anti-PD-1 Antibody Presented at American Society of Clinical Oncology Annual Meeting
6. Early Data Presented at ASCO Show Potential of RAD001 to Enhance Efficacy of, and Overcome Resistance to, Breast Cancer Treatments
7. New Analyses Presented at ASCO Reaffirmed Efficacy and Safety of TORISEL in Patients With Advanced Kidney Cancer
8. Data To Be Presented at ASCO Supports Potential of Peregrines Cotara(R) for the Treatment of Brain Cancer
9. About 60 Clinical Studies Regarding Schering-Ploughs Oncology Compounds Will be Presented at ASCO
10. Two DOXIL(R) Studies to be Presented at American Society of Clinical Oncology (ASCO) Annual Meeting
11. Treprostinil Data Presented at American Thoracic Society Conference Demonstrates Significant Clinical Progress in All Four Routes of Administration
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... BEIJING , Dec. 24, 2014  The International Trade ... by ResMed (RMD) against BMC Medical. In a notice issued ... and found that ResMed,s patent on its humidifier was invalid. ... decision a "monumental win". "We are very excited with the ... the position that we have taken since the very beginning ...
(Date:12/24/2014)... and LONDON , December ... orthopedic industry are expected to grow at an average ... terms of value and volume. Hip, knee and spine ... world while in emerging economies they have a lower ... are challenging the use of composites. Non-metallic orthopedic devices ...
(Date:12/24/2014)... DIEGO , Dec. 23, 2014 ResMed (NYSE: ... significant patent infringement action against Chinese medical device manufacturer BMC ... (ITC) ruled today that BMC,s masks listed below infringe ResMed,s ... or selling these masks in the United States ... iVolve N2 nasal mask , Willow nasal pillows mask ...
Breaking Medicine Technology:ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 2Use of Composites in Orthopedic Industry to Reach $596 Million by 2020 3ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2
... Pharmaceutical Care Management Association (PCMA) President and CEO ... Pentagon,s new budget proposal which includes a provision encouraging ... to save money: "The Pentagon,s budget proposal ... of generics and mail-service pharmacies reduces costs and enhances ...
... 15, 2011 Boston Scientific Corporation (NYSE: ... technologies to treat peripheral chronic total occlusions (CTOs).  These ... portfolio of devices for lower extremity peripheral artery disease. ... in November 2010 from S.I. Therapies, Ltd., based in ...
Cached Medicine Technology:Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 2Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 3Boston Scientific Acquires Two Novel Technologies to Treat Peripheral Chronic Total Occlusions 4
(Date:12/26/2014)... 26, 2014 Yisrayl Hawkins, Pastor at The ... letter in light of the Ferguson, Missouri unrest. Yisrayl starts ... unrest and explains why it has only increased. , ... even created. He says there is a very specific reason ... says there is a set of rules, or Laws that ...
(Date:12/26/2014)... Orlando, FL (PRWEB) December 26, 2014 ... visitor health insurance in the USA, announced today a ... to assist members in choosing the right plan for ... take the complexity out of the selection process when ... premiums by age group with only a few clicks. ...
(Date:12/25/2014)... The microscopy market is estimated to grow at ... by 2019. Optical microscopy is the largest segment ... segment is expected to show the fastest growth ... nanotechnology, technological advancements, and increasing federal support to ... Full Copy of Report @ http://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html ...
(Date:12/25/2014)... 26, 2014 The report “TS-1 (Colorectal ... on the current treatment landscape, unmet needs, current pipeline ... is an anti-cancer drug which is typically used for ... also used for treating gastric cancer and pancreatic cancer. ... The drug was first approved in 1999 in Japan ...
(Date:12/25/2014)... Recently, Dylan Queen, a famous online company supplying women’s ... discounted prom dresses, most of which are priced under ... company, the promotion is valid until Jan. 22, 2015; ... UK market. , The prom dresses in this new ... A-line strapless, empire strapless chiffon, one shoulder, floor-length, V-neck ...
Breaking Medicine News(10 mins):Health News:Yisrayl Hawkins Pleads for Peace in Ferguson and Beyond in New Open Letter 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 2Health News:India Network Health Insurance Announces new Comprehensive Pre-existing Condition Coverage policy for Visitors to the United States 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 2Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 3Health News:Microscopy Market Hit to $5,756.0 Million by 2019 - New Research Report by MarketsandMarkets 4Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 2Health News:TS-1 Colorectal Cancer Market Analysis and Forecast to 2023 Report at RnRMarketReserach.com 3Health News:Dylan Queen: Cheap Prom Dresses for the UK Market 2
... The Damon Runyon Cancer Research Foundation named ... April 2010 Clinical Investigator Award Committee review. ... outstanding early career physician-scientists conducting patient-oriented cancer research ... the nation,s leading scientists and clinicians. Each will ...
... new magnetic resonance imaging technology that could revolutionise the ... take a major step forward as a 7m research ... Hyperpolarisation with parahydrogen is a technique developed at the ... resonance imaging (MRI), the scanning technology widely used in ...
... ... release of their new Alpha 3C™ formula, designed to naturally support focus, calmness ... ... of premium dietary supplements, announces the release of their new Alpha 3C™ formula, ...
... therapy made from a human protein significantly decreases disease ... a new asthma therapy for patients who do not ... in an animal model were presented at The Endocrine ... protein, insulin-like growth factor binding protein-3 (IGFBP-3), uniquely inhibits ...
... ... order to attract patients, compete effectively, grow their revenues, counter the declining economy and ... ... doctor and physician marketing firm Heathcare Success Strategies , doctors are increasingly resorting ...
... ... achieve greater athletic outcomes and increase their performance. , ... Pittsburgh, PA (PRWEB) June 28, ... premiere health care facilities, is an organization of physicians and health care professionals ...
Cached Medicine News:Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 2Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 3Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 4Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 5Health News:Damon Runyon Cancer Research Foundation awards $3.1M to 8 top young clinical investigators 6Health News:New scanning technology developed in £7M research center 2Health News:Purity Products Releases Alpha 3C 2Health News:Experimental nonsteroidal treatment of asthma shows promise 2Health News:Doctors and Medical Groups Increasingly Embrace Physician Marketing to Counter Changes in Health Care 2Health News:Allegheny Medical's SportsCare Programs Combine Lifestyle, Fitness and Behavior Management with Quality Medical Treatments 2
... offers three-dimensional VCS technology, ... and efficiency in white ... analysis. With its reputation ... HmX is an affordable ...
... LH 755 simplifies and automates ... expert automation and advanced technologies ... reliable, accurate results every time. ... slide quality with its slide-on-slide ...
... CKX microscopes utilize the infinity-corrected ... and operability in cell checking. ... inverted microscope suited to routine ... fields--from tissue culture and embryology ...
... was designed from the ground-up with ergonomic ... height and most adjustable observation tube on ... that every user can adjust the microscope ... flexibility helps the operator maintain an upright, ...
Medicine Products: